Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

761
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
761
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

391
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
391
Peripherally and Centrally Acting Muscle Relaxants: A Comparison01:09

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

3.6K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated quantification of skin Gb3 load and white matter lesion assessment in Fabry disease.

Orphanet journal of rare diseases·2026
Same author

Specific HLA-DRB1 Alleles Associate With Anti-Caspr1 and Anti-CNTN1 Autoantibodies in Autoimmune Nodopathies.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

Intraepidermal nerve fiber density as a predictor of cardiac events in Fabry disease.

European heart journal open·2026
Same author

Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy.

Blood cancer discovery·2026
Same author

TrkA abundance is increased in cutaneous nerves in bortezomib-induced neuropathy.

Brain pathology (Zurich, Switzerland)·2026

Related Experiment Video

Updated: Aug 25, 2025

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.3K

Analgesic Medication in Fibromyalgia Patients: A Cross-Sectional Study.

H-C Aster1,2, D Evdokimov1, A Braun1

  • 1Department of Neurology, University Hospital Würzburg, Würzburg 97080, Germany.

Pain Research & Management
|October 17, 2022
PubMed
Summary

Many fibromyalgia syndrome (FMS) patients in Germany use "on-demand" pain medication, often nonsteroidal anti-inflammatory drugs (NSAIDs) or metamizole, which deviates from treatment guidelines. Further research is needed to optimize drug efficacy in FMS subgroups.

More Related Videos

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

5.1K
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

33.5K

Related Experiment Videos

Last Updated: Aug 25, 2025

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.3K
Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

5.1K
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

33.5K

Area of Science:

  • Pharmacology
  • Neurology
  • Rheumatology

Background:

  • Fibromyalgia syndrome (FMS) lacks an approved drug in Europe, with current guidelines recommending temporary use of amitriptyline, duloxetine, and pregabalin.
  • German S3 guideline recommendations for FMS management are not consistently followed in clinical practice.

Purpose of the Study:

  • To investigate the current medication practices for fibromyalgia syndrome (FMS) patients in Germany.
  • To assess the effectiveness of commonly used analgesics in FMS patients.
  • To explore the potential association between intraepidermal nerve fiber density and treatment response.

Main Methods:

  • Cross-sectional study involving systematic interviews with 156 FMS patients.
  • Patients were stratified based on intraepidermal nerve fiber density.
  • Data collected on drug usage, administration regimens, and self-rated pain relief.

Main Results:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) (41.0%), metamizole (22.4%), and amitriptyline (12.8%) were the most frequently used drugs for FMS pain.
  • The majority of patients (53.9%) used analgesics "on demand" rather than daily.
  • NSAIDs and metamizole showed the best pain reduction, with median relief of 2 points on a 0-10 scale.

Conclusions:

  • Current FMS medication practices in Germany, particularly the prevalent "on-demand" use of NSAIDs and metamizole, do not align with established guidelines.
  • The hypothesis linking decreased intraepidermal nerve fiber density to improved neuropathic pain drug efficacy was not supported.
  • There is a need for more randomized clinical trials to evaluate drug effectiveness in specific FMS patient subgroups.